Cannovex BV provides pharmacies with the highest purity cannabidiol (CBD) as Active Pharmaceutical Ingredient.
Latest news
CANNOVEX receives EUR 0.5 million grant for development of nanofibrous films for transmucosal uptake of cannabinoids.
Diepenbeek, Belgium, 14 October 2020 – Cannovex BV (the ‘Company’ or ‘Cannovex), a developer of cannabinoid-based medicines today announces that it has been awarded a EUR 0.5 million development grant…
Read MoreIndustry concepts of cannabinoid-BASED medicines
Medicinal cannabis, cannabinoid-based medicine,… what’s in a name?
This infographic provides an overview of the various concepts.
Cannovex is focusing on concept 4.0 – i.e. the development of cannabinoid-based medicines.
Our Partners
Cannovex has entered into partnerships with universities and institutions for scientific research and business development, both in Belgium as in The Netherlands. Cannovex is open for partnerships to accomplish its mission to improve patients’ lives by developing cannabinoid-based medicines.
Cannovex BV
BE0656.491.644
Agoralaan Abis
3590 Diepenbeek
Belgium
© 2020 – Cannovex BV – All rights reserved
Tel: +32 11 28 69 00
E-mail: info@www.cannovex.com